Portfolio company
Full-Life Technologies
Country not known yet
Raised
Not known yet
Latest stage
Not known yet
Rounds recorded
Not known yet
Backed by
1 investor
Sectors
About
This company develops radiopharmaceuticals and radionuclide drug conjugates to treat cancer patients through targeted alpha therapy.
SourceFunding history · 0
No rounds recorded yet. The agent looks for them over time.
Similar companies
Alpha-9 Theranostics
This clinical-stage biotechnology company develops targeted radiopharmaceuticals to treat cancer patients by delivering radiation directly to tumours while sparing healthy tissue.
Aktis Oncology
This biotechnology company develops alpha-emitting radiopharmaceuticals to treat patients with solid tumor cancers.
Alpha-9
Alpha-9 Oncology develops targeted radiopharmaceuticals and imaging compounds for the treatment of patients with various types of cancer.
Actithera
This biotechnology company develops targeted radioligand therapies to treat cancer patients by delivering radioactive isotopes directly to solid tumours.
Actithera Group
This company develops radioligand therapies to treat cancer patients by delivering radiation directly to solid tumours while sparing healthy tissue.
Akiram Therapeutics
This biotech company develops targeted radiopharmaceuticals and radioimmunotherapies for patients with solid tumours and metastatic cancers.
Rayze Bio
RayzeBio develops targeted radiopharmaceutical therapies using alpha-emitting isotopes to treat patients with solid tumours and other cancers.
Ariceum Therapeutics
This clinical-stage biotechnology company develops targeted radiopharmaceutical therapies for the diagnosis and treatment of aggressive, hard-to-treat cancers.